Alterations in the hepatic transcriptional landscape after RNAi mediated ApoB silencing in cynomolgus monkeys

Atherosclerosis

Volumn 242, Issue 2, 2015, Pages 383-395

  Hamza, M Sabry ^a   Kumar, Chanchal ^a   Chia, Ser Mien ^a   Anandalakshmi, Vidhya ^a   Boo, Nicole ^a   Strapps, Walter ^a   Robinson, Michael ^a   Caguyong, Michelle ^a   Bartz, Steven ^a   Tadin Strapps, Marija ^a   van Gool, Alain ^a   Shih, Shian Jiun ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

APOB; Cholesterol; Cynomolgus monkeys; NHP; Non human primates; RNAi; SiRNA

Indexed keywords

2,2 DILINOLEYL 4 (2DIMETHYLAMINOETHYL) [1,3] DIOXOLANE; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; BUTYL METHACRYLATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; NANOCARRIER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CHOLESTEROL; LIPID; NANOPARTICLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; GENE ONTOLOGY; GENE SILENCING; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER; LIVER BIOPSY; MACACA FASCICULARIS; MALE; MICROARRAY ANALYSIS; NANOENCAPSULATION; NONHUMAN; PRIMATE MODEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RNA INTERFERENCE; RNA TRANSCRIPTION; ANIMAL; BIOPSY; BLOOD; CHEMISTRY; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; GENOME; GENOMICS; HUMAN; METABOLISM; PATHOLOGY; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; APOLIPOPROTEINS B; BIOPSY; CHOLESTEROL; GENE EXPRESSION REGULATION; GENOME; GENOMICS; HUMANS; LIPID METABOLISM; LIPIDS; LIVER; MACACA FASCICULARIS; MALE; NANOPARTICLES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BIOSYNTHESIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84939142073     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.07.032     Document Type: Article

References (75)

1. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340(2):115-126.
2. Narain V.S., et al. Clinical correlation of multiple biomarkers for risk assessment in patients with acute coronary syndrome. Indian Heart J. 2008, 60(6):536-542.
3. Wouters K., et al. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. Clin. Chem. Lab. Med. 2005, 43(5):470-479.
4. Cannon C.P., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004, 350(15):1495-1504.
5. Ridker P.M., et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 2005, 352(1):20-28.
6. Zimmermann T.S., et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441(7089):111-114.
7. St-Pierre A.C., et al. Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am. J. Cardiol. 2006, 97(7):997-1001.
8. Talmud P.J., et al. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler. Thromb. Vasc. Biol. 2002, 22(11):1918-1923.
9. Lamarche B., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the quebec cardiovascular study. Circulation 1996, 94(3):273-278.
10. Benn M. Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. Atherosclerosis 2009, 206(1):17-30.
11. Crooke R.M. Antisense oligonucleotides as therapeutics for hyperlipidaemias. Expert Opin. Biol. Ther. 2005, 5(7):907-917.
12. Visser M.E., et al. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur. Heart J. 2012, 33(12):1451-1458.
13. Bell D.A., et al. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vasc. Health Risk Manag. 2012, 8:651-659.
14. Bell D.A., Hooper A.J., Burnett J.R. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin. Investig. Drugs 2011, 20(2):265-272.
15. Tadin-Strapps M., et al. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J. Lipid Res. 2011, 52(6):1084-1097.
16. Shi B., et al. Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery. J. Histochem. Cytochem. 2011, 59(8):727-740.
17. Summerton J.E. Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr. Top. Med. Chem. 2007, 7(7):651-660.
18. Grunweller A., et al. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 2003, 31(12):3185-3193.
19. Chen Z., et al. Proof-of-concept studies for siRNA-mediated gene silencing for coagulation factors in rat and rabbit. Mol. Ther. Nucleic Acids 2015, 4:e224.
20. Feingold K.R. Does inhibition of apolipoprotein B synthesis produce foie gras?. J. Lipid Res. 2010, 51(5):877-878.
21. Ason B., et al. ApoB siRNA-induced liver steatosis is resistant to clearance by the loss of fatty acid transport protein 5 (fatp5). Lipids 2011, 46(11):991-1003.
22. Tep S., et al. Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing. J. Lipid Res. 2012, 53(5):859-867.
23. Mihaila R., et al. Lipid nanoparticle purification by spin centrifugation-dialysis (SCD): a facile and high-throughput approach for small scale preparation of siRNA-lipid complexes. Int. J. Pharm. 2011, 420(1):118-121.
24. Semple S.C., et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 2010, 28(2):172-176.
25. Shi B., Abrams M. Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery. J. Histochem. Cytochem. 2013, 61(6):407-420.
26. Kelsey D.E., et al. Laboratory validation of a low density lipoprotein apolipoprotein-B assay. Clin. Biochem. 2014, 47(16-17):211-215.
27. Nakajima K., et al. Apolipoprotein B-48: a unique marker of chylomicron metabolism. Adv. Clin. Chem. 2014, 64:117-177.
28. Irizarry R.A., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264.
29. Team, R.C., R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing 2012, Vienna, Austria.
30. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 1995, 57(1):289-300.
31. Haider S., et al. BioMart central portal-unified access to biological data. Nucleic Acids Res. 2009, 37(Web Server issue). W23-7.
32. Falcon S., Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007, 23(2):257-258.
33. Zhang X., Goodsell J., Norgren R.B. Limitations of the rhesus macaque draft genome assembly and annotation. BMC Genom. 2012, 13:206.
34. Berger J.H., Charron M.J., Silver D.L. Major facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolism. PLoS One 2012, 7(11):e50629.
35. Miyata K., et al. Elevated mature macrophage expression of human ABHD2 gene in vulnerable plaque. Biochem. Biophys. Res. Commun. 2008, 365(2):207-213.
36. Stagos D., et al. Aldehyde dehydrogenase 1B1: molecular cloning and characterization of a novel mitochondrial acetaldehyde-metabolizing enzyme. Drug Metab. Dispos. 2010, 38(10):1679-1687.
37. Lee S.K., et al. Genetic association between functional haplotype of collagen type III alpha 1 and chronic hepatitis B and cirrhosis in Koreans. Tissue Antigens 2008, 72(6):539-548.
38. Wasmuth H.E., et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009, 137(1). 309-19, 319 e1-3.
39. Sahin H., et al. Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology 2012, 55(5):1610-1619.
40. Daly A.K. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu. Rev. Pharmacol. Toxicol. 2012, 52:21-35.
41. Pirmohamed M. Genetics and the potential for predictive tests in adverse drug reactions. Chem. Immunol. Allergy 2012, 97:18-31.
42. Daly A.K., et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 2009, 41(7):816-819.
43. Alfirevic A., et al. In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers. Genome Med. 2012, 4(6):51.
44. Oliva J., et al. Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesis. Exp. Mol. Pathol. 2008, 84(2):102-112.
45. Borkham-Kamphorst E., Drews F., Weiskirchen R. Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin-1beta through nuclear factor-kappaB activation. Liver Int. 2011, 31(5):656-665.
46. Susaki E., Nakayama K., Nakayama K.I. Cyclin D2 translocates p27 out of the nucleus and promotes its degradation at the G0-G1 transition. Mol. Cell Biol. 2007, 27(13):4626-4640.
47. Park T.J., et al. CCND2 polymorphisms associated with clearance of HBV infection. J. Hum. Genet. 2010, 55(7):416-420.
48. Li D., Zhao H., Gelernter J. Further clarification of the contribution of the ADH1C gene to vulnerability of alcoholism and selected liver diseases. Hum. Genet. 2012, 131(8):1361-1374.
49. Ding X.R., et al. Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs. Pharmacogenomics J. 2008, 8(1):61-70.
50. Kamynina E., et al. A novel mouse Nedd4 protein suppresses the activity of the epithelial Na+ channel. Faseb J. 2001, 15(1):204-214.
51. Chen C., Matesic L.E. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev. 2007, 26(3-4):587-604.
52. Angers M., et al. Mfsd2a encodes a novel major facilitator superfamily domain-containing protein highly induced in brown adipose tissue during fasting and adaptive thermogenesis. Biochem. J. 2008, 416(3):347-355.
53. Aitken A.E., Richardson T.A., Morgan E.T. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol. 2006, 46:123-149.
54. Chung S., et al. Targeted deletion of hepatocyte ABCA1 leads to very low density lipoprotein triglyceride overproduction and low density lipoprotein hypercatabolism. J. Biol. Chem. 2010, 285(16):12197-12209.
55. Li G., et al. Effects of antisense-mediated inhibition of 11beta-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. J. Lipid Res. 2011, 52(5):971-981.
56. Crooke R.M., et al. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 2005, 46(5):872-884.
57. Shen X., et al. Identification of genes affecting apolipoprotein B secretion following siRNA-mediated gene knockdown in primary human hepatocytes. Atherosclerosis 2012, 222(1):154-157.
58. Carmena R., Duriez P., Fruchart J.C. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004, 109(23 Suppl. 1). III2-7.
59. Linton M.F., et al. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest 1993, 92(6):3029-3037.
60. Skogsberg J., et al. Transcriptional profiling uncovers a network of cholesterol-responsive atherosclerosis target genes. PLoS Genet. 2008, 4(3):e1000036.
61. Watanabe K., et al. In vivo siRNA delivery with dendritic poly(L-lysine) for the treatment of hypercholesterolemia. Mol. Biosyst. 2009, 5(11):1306-1310.
62. Das R., et al. Macrophage gene expression and foam cell formation are regulated by plasminogen. Circulation 2013, 127(11). 1209-18, e1-16.
63. Iwata H., Aikawa M. Liver-artery interactions via the plasminogen-CD36 axis in macrophage foam cell formation: new evidence for the role of remote organ crosstalk in atherosclerosis. Circulation 2013, 127(11):1173-1176.
64. Tsuchiya K., et al. FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. Cell Metab. 2012, 15(3):372-381.
65. Katoh M., Katoh M. Human FOX gene family (review). Int. J. Oncol. 2004, 25(5):1495-1500.
66. Wang L., et al. Fine mapping study reveals novel candidate genes for carotid intima-media thickness in Dominican Republican families. Circ. Cardiovasc Genet. 2012, 5(2):234-241.
67. Rosenson R.S., et al. Modulating peroxisome proliferator-activated receptors for therapeutic benefit? biology, clinical experience, and future prospects. Am. Heart J. 2012, 164(5):672-680.
68. van Bilsen M., van Nieuwenhoven F.A. PPARs as therapeutic targets in cardiovascular disease. Expert Opin. Ther. Targets 2010, 14(10):1029-1045.
69. Lu Y., et al. Yin Yang 1 promotes hepatic gluconeogenesis through upregulation of glucocorticoid receptor. Diabetes 2013 Apr, 62(4):1064-1073.
70. Iguchi H., et al. SOX6 attenuates glucose-stimulated insulin secretion by repressing PDX1 transcriptional activity and is down-regulated in hyperinsulinemic obese mice. J. Biol. Chem. 2005, 280(45):37669-37680.
71. Peng S., et al. TCF7L2 gene polymorphisms and type 2 diabetes risk: a comprehensive and updated meta-analysis involving 121 174 subjects. Mutagenesis 2013, 28(1):25-37.
72. Cooper J.D., et al. The candidate genes TAF5L, TCF7, PDCD1, IL6 and ICAM1 cannot be excluded from having effects in type 1 diabetes. BMC Med. Genet. 2007, 8:71.
73. Tsutsumi K., Hagi A., Inoue Y. The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals. Biol. Pharm. Bull. 2001, 24(5):579-581.
74. Yin W., et al. Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J. Lipid Res. 2012, 53(1):51-65.
75. Rakhshandehroo M., et al. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One 2009, 4(8):e6796.